IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans

Ustekinumab is currently being explored for the treatment of alopecia areata. Here, our work in a murine model and in human patients indicates that neutralization of the IL-12 and IL-23 pathways does not ameliorate disease.